The FDA recently approved Harvoni (ledipasvir/sofosbuvir), a new combination oral medication for the treatment of hepatitis C that stops the replication of the virus.
What is Harvoni?
Harvoni 90 mg/400 mg tablets are a once-daily treatment that can be used without injectable pegylated interferon alpha (Pegintron, Pegasys) or oral ribavirin (Copegus, Ribasphere, Rebetol).
Why is Harvoni different from other hepatitis C treatments?
Harvoni is unique because it is the first combination pill approved to treat chronic hepatitis C genotype 1 infection and it DOES NOT require combination treatment with pegylated interferon or ribavirin—medications that use to be first line therapy, but have serious side effects. See More